David J Harris

This inventor holds 32 USPTO granted patents and 9 published patent applications and 8 EPO patents. Top assignees: Genzyme Corporation, University of Michigan, University of Iowa Research Foundation. Active years: 1997-2017.

USPTO Granted Patents = 32 (Patent Applications = 9)

% Patents Active = 71.9

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 6.3

ph-index = 16

Forward Citations = 810(Granted Patents)

Company Filing History:

University of Michigan

patents

1 out of 925

University of Iowa Research Foundation

patents

where one patent can have more than one assignee

Years Active: 1997-2017

Loading Chart...

Areas of Expertise:

Glucosylceramide Synthase Inhibitors

Amide Dendrimer Compositions

UDP-Glucose Synthesis

N-Acylsphingosine Glucosyltransferase Inhibitors

Amino Ceramide Compounds

Cationic Amphiphiles

Intracellular Delivery

Gene Therapy

Cell Transfections

Therapeutic Molecules

Organ-Specific Targeting

Plasmid Delivery

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9745294 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2017-08-29),

2. 9744153 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2017-08-29),

3. 9272996 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2016-03-01),

4. 9066972 - Amide dendrimer compositions (2015-06-30),

5. 8940776 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2015-01-27),

6. 8900560 - Amide dendrimer compositions (2014-12-02),

7. 8425887 - Amide dendrimer compositions (2013-04-23),

8. 8309593 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2012-11-13),

9. 8304447 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2012-11-06),

10. 7615573 - Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors (2009-11-10),

11. 7253185 - Amino ceramide-like compounds and therapeutic methods of use (2007-08-07),

12. 7196205 - [object Object] (2007-03-27),

13. 6916802 - Amino ceramide-like compounds and therapeutic methods of use (2005-07-12),

14. 6383814 - Cationic amphiphiles for intracellular delivery of therapeutic molecules (2002-05-07),

15. 6331524 - Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy (2001-12-18),

Title: The Inventive World of David J Harris: A Pioneer in Medical Innovations

Introduction:

David J Harris, a prolific inventor based in Lexington, MA (US), has made significant contributions to the field of medical innovations. With an impressive portfolio of 32 patents, Harris continues to push the boundaries of science and technology in the pursuit of better health outcomes.

Latest Patents:

Among Harris' latest patents is the groundbreaking discovery of 2-acylaminopropoanol-type glucosylceramide synthase inhibitors. These compounds have shown promise in treating a range of conditions, including polycystic kidney disease. The innovative treatment methods underscore Harris' commitment to addressing complex medical issues through cutting-edge research.

Career Highlights:

Having worked at esteemed institutions such as Genzyme Corporation and the University of Michigan, Harris has garnered extensive experience in the biotechnology and healthcare sectors. His keen insights and dedication to innovation have earned him a reputation as a leader in the field.

Collaborations:

Throughout his career, Harris has collaborated with top minds in the industry, including esteemed coworkers Craig S Siegel and Edward R Lee. Together, they have leveraged their expertise to drive forward groundbreaking research and development initiatives that have the potential to revolutionize the medical field.

Conclusion:

In conclusion, David J Harris stands as a testament to the power of innovation and perseverance in driving meaningful change. His pioneering work in medical inventions serves as an inspiration to aspiring inventors and researchers worldwide, as he continues to make strides in improving healthcare outcomes for the betterment of society.